This week, Carina discusses how to transition into a career in biotech when you don’t have lab experience. Plus, handling difficult interviews and getting a “dry” promotion.

Proteins have evolved to excel at everything from contracting muscles to digesting food to recognizing viruses. To engineer better proteins, including antibodies, scientists often iteratively mutate the amino acids - the units that are arranged in a sequence to make up proteins - in different positions until the resulting protein has an improved function, like eliciting a stronger immune response or capturing carbon dioxide from the atmosphere more efficiently.

Breaking the Cycle of Inflammation in Parkinson’s Disease 7/15/2024

5 Neuro Data Readouts to Watch in the Second Half of 2024 7/15/2024

SignalChem Biotech, World Leader in Kinases, Is Now Part of Sino Biological 7/15/2024

Opinion: Congress Must Reauthorize FDA Program for Pediatric Rare Diseases 7/15/2024

A method to screen a wide variety of drug candidates without laborious purification steps could advance the fight against drug-resistant bacteria.

Efforts to combat the increasing threat of drug-resistant bacteria are being assisted by a new approach for streamlining the search for antimicrobial drug candidates, pioneered by researchers at Hokkaido University, led by Assistant Professor Kazuki Yamamoto and Professor Satoshi Ichikawa of the Faculty of Pharmaceutical Sciences.

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track Designation for AB-1005, which is being developed for moderate Parkinson's disease. AB-1005 has also been awarded the Innovation Passport, the United Kingdom Medicines and Healthcare products Regulatory Agency (UK MHRA) innovative medicine designation, for the treatment of Parkinson's disease.